0.1930
+0.0280
+(16.97%)
At close: April 17 at 4:00:00 PM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Robert Louis Thast | Founder, Interim CEO & Chairman | -- | -- | 1954 |
| Mr. Ralph F. Proceviat CPA | CFO & Director | -- | -- | 1950 |
| Dr. Younes Achkire Ph.D. | Executive VP of Product Engineering & COO | -- | -- | -- |
| Mr. Ali Reza Sodagar | Legal Advisor & Independent Director | -- | 56.27k | -- |
| Ms. Jaclyn Thast | Operations Manager & Corporate Secretary | -- | -- | -- |
| Dr. Andrew M. Hernandez | Head of Imaging Technology | -- | -- | -- |
Izotropic Corporation
- Sector:
- Healthcare
- Industry: Diagnostics & Research
Description
Izotropic Corporation, a research and development company, develops diagnostic products for detecting breast cancers. It develops and commercializes IzoView, a CT diagnostic imaging device with a platform of targeted uses. Izotropic Corporation was incorporated in 2016 and is headquartered in Surrey, Canada.
Corporate Governance
Izotropic Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
April 1, 2025 at 10:59 AM UTC
Izotropic Corporation Earnings Date